DiaSorin
DiaSorin Gets FDA 510(k) Clearance for Molecular CMV Test
The test, which runs on the company's Liaison MDx system, is designed for use with both saliva swab and urine specimens from newborns 21 days old or younger.
DiaSorin Q3 Revenues Dip 5 Percent as COVID-19 Test Sales Fall
The firm said revenue is still up for the first nine months year-over-year on strong non-COVID immunodiagnostics and molecular diagnostics sales.
DiaSorin Gets $31M BARDA Funding for Point-of-Care Instrument
The Italian firm said the Liaison NES will help improve access to testing for bacterial and viral diseases through an easy-to-use instrument running lower cost assays.
DiaSorin Gains FDA 510(k) Clearance for COVID-19 PCR Test
The assay is one of a few that have received full FDA clearance for COVID-19, which the agency has been encouraging companies to pursue.
DiaSorin Posts 32 Percent Jump in Q2 Revenues
The revenue growth was driven by higher sales of non-COVID-19 molecular diagnostic and immunodiagnostic products.